AmerisourceBergen distributes pharmaceutical products and services. From a technical viewpoint, the stock reaches an interesting entry point which shows a good potential.
AmerisourceBergen is trading at a very low level in relation to historic benchmark as shown by the ratio “enterprise value/revenue” at 0.11x. Moreover, the price earnings ratio should be 13.0x, estimated in 2012. According to Thomson-Reuters' consensus, the average target price is set at $ 45, which represents a potential gain of 24 % on the basis of the current price.
Technically, after a recent downward trend distinguished by a bearish gap, the AmerisourceBergen's share comes in contact with important levels (short and mid-term). These supports situated at $35.60 and $35.90 could stop the bearish trend.
Therefore, the proximity at support area of $35.6 could allow investors to take a buy position at this price. Our first target will be the $37.8 resistance and then we could aim at $42 long-term resistance. We should cover this position with a stop loss below $ 35.60.
Cencora, Inc. specializes in distributing pharmaceutical products. The group supplies generic and name-brand medications, OTC healthcare products, and home care equipment to healthcare providers (hospitals, clinics, pharmacies, physicians, etc.) located in the United States and Canada. The group also offers services to physicians and patients (support and reimbursement assistance services, prescription management services, nursing services, home injection and perfusion services, etc.).
CENCORA, INC. 
